Skip to search formSkip to main contentSkip to account menu

XL147

Known as: PI3K Family Kinase Inhibitor XL147 
An orally bioavailable small molecule, targeting the class I phosphatidylinositol 3 kinase (PI3K) family of lipid kinases, with potential… 
National Institutes of Health

Related topics

Related topics

4 relations
NCIt Antineoplastic Agent TerminologySAR245408

Broader (2)

QuinoxalinesSulfonamides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
NES 1 / KLK 10 promotes trastuzumab resistance via activation of PI 3 K / AKT signaling pathway in gastric cancer † Running title : Role of NES 1 / KLK 10 in trastuzumab resistance
Minghua Yu Department of Hematology/oncology, Pudong Hospital affiliated to Fudan University, 2800 Gongweilu, Huinan Town, Pudong… 
2017
2017
Optical metabolic imaging measures early drug response in an allograft murine breast cancer model (Conference Presentation)
Previous work has shown that cellular-level Optical Metabolic Imaging (OMI) of organoids derived from human breast cancer cell… 
2015
2015
Correction: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
2013
2013
Cancer Therapy : Preclinical Human Breast Cancer Cells Harboring a Gatekeeper T 798 M Mutation in HER 2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER 2
  • 2013
  • Corpus ID: 31246422
Purpose: Mutations in receptor tyrosine kinase (RTK) genes can confer resistance to receptor-targeted therapies. A T798M mutation… 
2010
2010
A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors.
3078 Background: Upregulation of PI3K pathway signaling is associated with tumor resistance to P and C. The oral selective Class… 
2010
2010
A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors.
3070 Background: The PI3K pathway is frequently dysregulated in cancer cells and has been implicated as a mechanism of resistance… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)